Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Alternative Treatments: Identifying Options After FDA Reclassification of Specific Peptides Bergen Total Health